Intranasal Dexmedetomidine for Adult Patients Undergoing Phacoemulsification Cataract Surgery

Cataract Clinical Trial

Official title: A Randomized Controlled Trial of Intranasal Dexmedetomidine for Adult Patients Undergoing Phacoemulsification Cataract Surgery

Status Recruiting

Clinical Trial Summary

The investigators designed this study to examine whether the intranasal dexmedetomidine, as a preoperative drug, could improve the satisfaction of adult patients undergoing phacoemulsification cataract surgery.

Clinical Trial Description

This is a prospective, double-blind, randomized controlled study. Patients over 65 years old were selected for phacoemulsification combined with intraocular lens implantation under topical anesthesia. Participants were randomly divided into two groups: dextrometropine group and placebo group, and were masked until the end of this study. Approximately 45 - 60 minutes before surface anesthesia, patients in the dextrometropine group were given dextrometropine (1.0μg.kg-1), patients in the placebo group were given the same amount of saline. The primary end point of this study is the patient satisfaction. Patient satisfaction was assessed using a 3-point satisfaction score on a scale. Anxiety of perioperative patients was assessed using a 4-point anxiety score on a scale. Secondary endpoints include blood pressure, heart rate, blood oxygen saturation, operation time, operative complications and adverse drug reactions. ;

Related Conditions & MeSH terms

• Cataract
• Preoperative Sedation

• NCT number: NCT05698758
• Study type: Interventional
• Source: Guangzhou First People's Hospital
• Contact: Yuehong Zhang, PhD
• Phone: 86-02081048225
• Email: carmenzhangyh@163.com
• Status: Recruiting
• Phase: N/A
• Start date: January 10, 2023
• Completion date: March 31, 2023